drugset / Trial / NCT02352402

The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

NCT02352402 ↗

Phase 3 Unknown 487 enrolled J.M. ten Berg AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In the POPular CABG study we investigate if the addition of ticagrelor, a drug that inhibits blood platelets from clotting, to treatment with aspirin will reduce the rate of saphenous vein graft occlusion as assessed with coronary computed tomography angiography at 1 year after coronary artery bypass grafting surgery.

Timeline

Start
2015-03
Primary completion
2020-08
Completion
2020-08

Outcome

Missed primary endpoint

paper CONCLUSIONS: In this randomized, placebo-controlled trial, the addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CABG. PMID 32862716 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 90 mg —